SAN DIEGO, Feb. 3, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI) (http://www.apricusbio.com) announced today the execution of a binding term sheet with NovaDel Pharma Inc. (“NovaDel”) (OTCBB:NVDL) for the sale and license of rights in territories outside of the United States, Canada and Mexico to NovaDel’s NitroMist® (nitroglycerin sublingual spray), an FDA-approved nitrate vasodilator indicated for acute relief of an attack or acute prophylaxis of angina pectoris (chest pain) due to coronary artery disease (narrowing of the blood vessels that supply blood to the heart).
